GSK's boasts on triple therapy questioned in editorial

GlaxoSmithKline (LSE: GSK) has highlighted the publication of data on its triple therapy Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) in the New England Journal of Medicine (NEJM), but the UK pharma major might not want to draw so much attention to an accompanying editorial.

NEJM has published  findings on Trelegy, a therapy developed by GSK and its partner Innoviva (Nasdaq: INVA), from the IMPACT study, one of the largest ever conducted in patients with chronic obstructive pulmonary disease (COPD) with a history of exacerbation.

Findings from the study suggest that the triple combination is superior to the Relvar/Reo Ellipta (fluticasone furoate/vilanterol) and Anoro Ellipta (umeclidinium/vilanterol) dual therapies that were earlier developed by GSK, across multiple endpoints including exacerbations, lung function and quality of life.